IP Library Granted Patent US 11,851,383
Granted Patent B2
US 11,851,383 · App. 17/060,810 · Granted Dec 26, 2023

Automatic process platform for the production of astatine-211 [At-211]-radiopharmaceuticals

Inventors: Sture Lindegren (Kungsbacka, SE); Emma Aneheim (Gothenburg, SE)
Assignee: Alpha Therapy Solutions AB
C07B59/008A61K51/1045A61K51/1051C07B59/00G21G1/001C07B2200/05G21G2001/0094
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,851,383
App. No.
17/060,810
Granted
Dec 26, 2023
Kind
B2
Abstract

A system and method for automatic production of astatine-211 labeled molecules is described. The invention represents a significant advantage in the preparation of At-211 radiopharmaceuticals including better reproducibility, reduced production time and increased radiation safety. The invention also enables routine automatic synthesis of radiopharmaceuticals in a clinical setting, in conjunction or at short distance from a cyclotron unit capable of producing the radionuclide.

Claims (33)

1. A process for automatic synthesis of At-211 labeled molecules comprising:

isolating an At-211 nuclide from a solid irradiated Bi-209 target material;

dry-distilling the At-211 nuclide in a furnace system to provide a dry-distilled At-211;

condensing the dry-distilled At-211 by cooling in a cooling unit to obtain as a dry residue At-211;

eluting the dry residue At-211 with a transfer liquid that solvates the dry residue At-211 to provide an At-211 solvate;

introducing the At-211 solvate into a reaction vial, wherein said reaction vial comprises a precursor molecule adapted to bind At-211;

activating the At-211 in the At-211 solvate for to provide an activated At-211;

reacting the activated At-211 with said precursor molecule to provide the At-211 labeled molecules,

wherein the process is automatic from isolation of the At-211 nuclide to providing the At-211 labeled molecules.

2. The process of claim 1 , wherein automatically isolating the At-211 nuclide from the solid irradiated Bi-209 target material comprises scraping the solid irradiated bismuth Bi-209 target material to obtain an At-211 powder target material comprising the At-211 nuclide.

3. The process of claim 2 , wherein the scraping of the solid irradiated Bi-209 target material is performed using a scraping unit.

4. The process of claim 1 , wherein the transfer liquid is an organic solvent.

5. The process of claim 4 , wherein the organic solvent is evaporated from the reaction vial leaving a dry residue of At-211.

6. The process of claim 1 , wherein the transfer liquid is an oxidizes the At-211 solvate.

7. The process of claim 1 , wherein the transfer liquid reduces the At-211 solvate.

8. The process of claim 1 , further comprising

purifying the At-211 labeled molecules to provide a purified product.

9. The process of claim 1 , wherein an inert gas is used to transport the dry-distilled At-211 from a receptacle of the furnace system to the cooling unit ( 106 ) and to transport the transfer liquid within the furnace system.

10. The process of claim 1 , wherein a reduced pressure is applied while dry-distilling the At-211 nuclide to confine At-211 in the furnace system and to speed up rate of distillation.

11. The process of claim 1 , wherein the cooling unit is a cryotrap.

12. The process of claim 1 , wherein the precursor molecule is selected from the group comprising inorganic molecules, organic molecules such as non-proteins, proteins, peptides, antibodies or fragments thereof, and mixtures thereof.

13. The process of claim 8 , wherein the purifying is performed using a liquid chromatography or a high pressure liquid chromatography.

14. The process according to claim 1 , wherein the At-211 solvate comprises At-211 in one or more redox forms selected from the group comprising At-211<O>(ground form), At-211<n″>(reduced form) and At-211<m+>(oxidized form).

15. The process of claim 8 , further comprising sterile filtering the purified product.

16. The process of claim 2 , further comprising purifying the At-211 labeled molecules to provide a purified product.

17. The process of claim 16 , further comprising sterile filtering the purified product.

18. The process according to claim 4 , wherein an inert gas is used to transport the dry-distilled At-211 from a receptacle of the furnace system to the cooling unit and to transport the transfer liquid and the organic solvent within the furnace system.

19. The process according to claim 5 , wherein an inert gas is used to transport the dry distilled At-211 from a receptacle of the furnace system to the cooling unit and to transport the transfer liquid and the organic solvent within the furnace system.

20. The process according to claim 6 , wherein an inert gas is used to transport the dry distilled At-211 from a receptacle of the furnace system to the cooling unit and to transport the transfer liquid within the furnace system.

21. The process according to claim 7 , wherein an inert gas is used to transport the dry distilled At-211 from a receptacle of the furnace system to the cooling unit and to transport the transfer liquid within the furnace system.

22. The process according to claim 8 , wherein an inert gas is used to transport the dry distilled At-211 from a receptacle of the furnace system to the cooling unit and to transport transfer liquid within the furnace system.

23. The process according to claim 8 , wherein the purifying step is performed using a liquid chromatography or a high pressure liquid chromatography.

24. The process according to claim 9 , further comprising purifying the At-211 labeled molecules using a liquid chromatography or a high pressure liquid chromatography.

Assignments (1)
CHANGE OF NAME Recorded Sep 30, 2025
From: ALPHA THERAPY SOLUTIONS AB
To: ATLEY SOLUTIONS AB
Reel/Frame 072901/0384 →
Continuity (3)
Division 15530265
Provisional Application 62013678 · Jun 18, 2014
Related Publication 20210139389A1 · May 13, 2021